DCAT Week ’17: Pfizer, AstraZeneca, and Kite Pharma Discuss Biomanufacturing Strategy

As pharmaceutical companies intensify their product development in biologics, their supply requirements increase as well. The DCAT Week ’17 education program, Biomanufacturing 2027: Capacity, Investment, and Technology, gains insight from Pfizer, AstraZeneca, and Kite Pharma on the near-term and future direction of biomanufacturing. 

Market overview
Biologics’ share in the development and commercial portfolios of pharmaceutical companies is increasing, but to what extent, and which drugs are the most promising? That question will be addressed in an market overview in the DCAT Week ’17 education program, Biomanufacturing 2027: Capacity, Investment, and Technology, by Susan Dexter, Managing Director, Latham BioPharm Group, who will provide the latest developments of the biologics market. The presentation will examine current and projected product performance, including global growth rates with market estimates by molecular type and geography and provide a review of the top-selling biologics and pipeline candidates for innovator drugs and biosimilars.

Biomanufacturing strategies
With increased product development in biologics, pharmaceutical and biopharmaceutical companies and suppliers face crucial questions in their biomanufacturing strategies for drug substances. Several fundamental questions emerge:

  • Build in-house capacity or use external manufacturing?
  • Single-use or stainless steel bioreactors?
  • How to manage capacity and technology for large-volume versus niche products?
  • Can we meet goals in production economics while still assuring supply?
  • Will our biomanufacturing strategy of today meet our demands of tomorrow?

These questions will be addressed by leading biopharmaceutical executives at the DCAT Week ’17 education program, Biomanufacturing 2027: Capacity, Investment, and Technology.

Biomanufacturing 2027: A Vision for the Future:  Will the biomanufacturing systems of today suit the needs of the future? In the pharmaceutical industry, 10 years is a “short” future due to the length of time required to bring a product from discovery to commercialization. Multiple years are needed to build and validate a new manufacturing facility, and more than 20 years is needed to fully depreciate a drug substance biomanufacturing site.Roberto Silveira, Vice President, Biomanufacturing Sciences Group, Pfizer, shares his perspective on biomanufacturing of today and of the future in terms of technology, scale, facility type, and equipment.

Biomanufacturing Investment: The Hows, Whys, and Whats: Biopharmaceutical companies face crucial issues in managing supply for biologics, such as whether to build in-house capacity or use external partners, what type of capacity to invest in, and what technology or equipment to use. Stephen Hill, Vice President & General Manager, AstraZeneca, will offer the decision criteria and evaluations made by the company in meeting near-term supply needs.

Biomanufacturing for Niche Products.  Emerging pharmaceuticals, such as chimeric antigen receptor T cell (CAR T) therapies, offer promise for delivering targeted therapies in keeping with the promise of personalized medicines, but do the production economics work and how does biomanufacturing for these niche products differ from conventional biomanufacturing? Tim Moore, Executive Vice President, Technical Operations, Kite Pharma, will provide perspective using the experience gained from the company’s recently opened manufacturing facility for CAR T therapies.

Further information, including how to register, may be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The CDMO/CMO Report: Cell and Gene Therapies

Although a niche market, cell and gene therapy development and manufacturing continues to be an active area of investment by CDMOs/CMOs. Facing limited industry capacity, both pure-play CDMOs and bio/pharma companies with CDMO services continue to expand. A roundup of the latest expansions.

Pharma Innovation: AI in Drug Manufacturing

What is the potential of artificial intelligence (AI) in pharmaceutical manufacturing and what regulatory considerations come into play, including between CDMOs/CMOs and sponsor companies? The FDA has issued a discussion paper to highlight key issues and is seeking input from the industry.

Pharma Industry Outlook: What Lies Ahead?

With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

ROI in Pharma R&D Falls in Post-Pandemic Market

A recent analysis by the management consultancy firm, Deloitte, shows that the bio/pharma industry’s return on investment (ROI) in R&D has fallen in the post-pandemic market. Projected ROI in pharma R&D in 2022 fell to 1.2%, the lowest ROI observed in the 13 years since the firm has conducted the study.